Results 51 to 60 of about 62,633 (233)
Allergy, Asthma & Clinical Immunology, 2022 Background Allergic rhinitis is a risk factor for asthma development. In asthma, fibroblast progenitors, fibrocytes, are increased in the blood and bronchial mucosa following allergen exposure.
Marie-Ève Côté +5 more
doaj +1 more source
Allergy, EarlyView.This randomized, double‐blind, placebo‐controlled trial evaluated the effects of live probiotic and HT postbiotic B. longum CECT 7347 in adults with moderate–severe allergic rhinitis. Postbiotic supplementation for 8 weeks significantly reduced CSMS and dSS, exceeding the established CSMS MCID with a 33% greater improvement, when compared to placebo ...
Ana Cardoso +9 more
wiley +1 more source
Endotyping of non-allergic, allergic and mixed rhinitis patients using a broad panel of biomarkers in nasal secretions. [PDF]
PLoS ONE, 2018 BACKGROUND:Endotyping chronic rhinitis has proven hardest for the subgroup of non-allergic rhinitis (NAR) patients. While IgE-related inflammation is typical for allergic rhinitis (AR), no markers have been found that can be seen to positively identify ...
Christine L Segboer +3 more
doaj +1 more source
Allergy, EarlyView.High‐dose birch‐extract nasal challenge induced synchronous peaks at 4 weeks in serum specific IgE (sIgE) and basophil sensitivity. Mast cell sensitivity via tSPT and sIgG1 and sIgG4 responses peaked later, at 6–8 weeks. Preseasonal allergen exposure attenuated seasonal sIgE increase and prevented further rise in tSPT sensitivity.
N. J. Campion +18 more
wiley +1 more source
Медицинский совет, 2017 Allergic rhinitis as one of the most common non-infectious respiratory inflammatory diseases is a global public health problem. The course of allergic rhinitis, its effect on the pathology of other organs and systems, the likelihood of complications and ...
G. N. Nikiforova +3 more
doaj +3 more sources
Efficacy and safety of a novel nasal steroid, S0597, in patients with seasonal allergic rhinitis.
Annals of Allergy, Asthma & Immunology, 2015 BACKGROUND Allergic rhinitis (AR) poses a significant global burden with increasing prevalence. Although intranasal glucocorticosteroids are effective, older agents can have limiting side effects.
P. Badorrek +4 more
semanticscholar +1 more source
Allergy, EarlyView.ABSTRACT Background To achieve adequate symptom control, patients with allergic rhinitis (AR) often need to increase their medication dose or add other treatments (co‐medication). We aimed to perform a systematic review to compare the efficacy and safety of AR medications for increased dose versus co‐medication.
Bernardo Sousa‐Pinto +44 more
wiley +1 more source
Journal of Asthma and Allergy, 2010 Robert AnolikAllergy and Asthma Specialists, PC, Blue Bell, Pennsylvania, USAAbstract: Of the classes of pharmacotherapy for seasonal allergic rhinitis, intranasal corticosteroids are the preferred treatment and are recommended in practice guidelines as ...
Robert Anolik
doaj
Allergy, EarlyView.Studies suggest that type 2 inflammatory diseases are driven by overactivation of the IL4/IL13 pathway, manifesting differently in distinct tissues. We performed quantitative analyses using several large independent datasets to explore the interrelation of type 2 inflammatory diseases based on co‐prevalence, genetic predispositions, and transcriptomic ...
Jennifer D. Hamilton +19 more
wiley +1 more source
Allergology International, 2015 BACKGROUND Seasonal Allergic Rhinitis Caused by Japanese Cedar Pollinosis (SAR-JCP) is a most common allergic rhinitis, affecting about 40% in Japan, but the influence from SAR-JCP upon asthma is controversial. The purpose of this study is to investigate
M. Hojo +5 more
semanticscholar +1 more source